Episurf Medical (NASDAQ: EPIS B) has received another Notice of Allowance from the Canadian Intellectual Property Office (CIPO). The patent, entitled “System and method for creating a decision support material indicating damage to an anatomical joint”, relates to 3D-based assessment of joint lesions. 

“This is an important patent for Episurf in the field of medical imaging and surgical pre-planning, and we are happy to get it approved in strategically selected countries”, says Katarina Flodström, COO, Episurf Medical.  

CisionBlockPro\Cision\FeedItem Object
(
    [HtmlCompanyInformation:protected] => <p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><strong><span style="font-size:10pt">About Episurf Medical</span></strong></p>
<p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><em>Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.</em></p>
<p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><span style="font-family:arial,helvetica,sans-serif; font-size:10pt"><em>This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 10:30 CET on 3 April, 2023.</em></span></p>
    [HtmlContact:protected] => <p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><strong><span style="font-size: 10pt; font-family: arial,helvetica,sans-serif;">For more information, please contact:</span></strong></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">P&aring;l Ryfors, CEO, Episurf Medical<br /></span><span style="font-size: 10pt; font-family: arial,helvetica,sans-serif;">Tel:</span><span style="font-size: 10pt;">+46 (0) 709 62 36 69<br /></span><span style="font-size: 10pt;">Email:&nbsp;</span><a href="mailto:pal.ryfors@episurf.com">pal.ryfors@episurf.com</a></p>
    [HtmlTitle:protected] => <h1 style="line-height:120%"><span style="font-family:arial,helvetica,sans-serif"><strong>New Canadian patent approval for Episurf Medical</strong></span></h1>
    [HtmlHeader:protected] => 
    [HtmlIntro:protected] => 
    [Body:protected] => Episurf Medical (NASDAQ: EPIS B) has received another Notice of Allowance from the Canadian Intellectual Property Office (CIPO). The patent, entitled “System and method for creating a decision support material indicating damage to an anatomical joint”, relates to 3D-based assessment of joint lesions. 
“This is an important patent for Episurf in the field of medical imaging and surgical pre-planning, and we are happy to get it approved in strategically selected countries”, says Katarina Flodström, COO, Episurf Medical.  
    [HtmlBody:protected] => <p style="margin-bottom:11px;margin-top:12px"><span><span style="font-size:11pt"><span><span style="font-family:arial,helvetica,sans-serif">Episurf Medical (NASDAQ: EPIS B) has received another Notice of Allowance from the Canadian Intellectual Property Office (CIPO). The patent, entitled <em>“System and method for creating a decision support </em><em>material indicating damage to an anatomical joint”</em>, relates to 3D-based assessment of joint lesions.&nbsp; </span></span></span></span></p>
<p><span><span style="font-size:11pt"><span><span style="text-autospace:none"><span style="font-family:arial,helvetica,sans-serif"><em>“</em><em>This is an important patent for Episurf </em><em>in the field of medical imaging and surgical pre-planning</em><em>, and we are happy to get it approved in strategically selected countries</em>”, says Katarina Flodström, COO, Episurf Medical.<em>&nbsp;&nbsp; </em></span></span></span></span></span></p>
    [ServiceCategories:protected] => Array
        (
            [0] => CisionBlockPro\Cision\ServiceCategory Object
                (
                    [ServiceName:protected] => EU Transparency SE
                    [Name:protected] => SeFsaCategoryCode
                    [Value:protected] => S6
                )
            [1] => CisionBlockPro\Cision\ServiceCategory Object
                (
                    [ServiceName:protected] => OMX Filing (OMX CNS)
                    [Name:protected] => OMX CategoryCode
                    [Value:protected] => 428
                )
            [2] => CisionBlockPro\Cision\ServiceCategory Object
                (
                    [ServiceName:protected] => Twitter
                    [Name:protected] => Twitter
                    [Value:protected] => 9341
                )
            [3] => CisionBlockPro\Cision\ServiceCategory Object
                (
                    [ServiceName:protected] => LinkedIn
                    [Name:protected] => LinkedIn
                    [Value:protected] => 14747
                )
            [4] => CisionBlockPro\Cision\ServiceCategory Object
                (
                    [ServiceName:protected] => Facebook
                    [Name:protected] => Facebook
                    [Value:protected] => 15237
                )
        )
    [LogoUrl:protected] => https://mb.cision.com/Public/14691/logo/96c29c854b230ac3_org.png
    [CompanyInformation:protected] => About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 10:30 CET on 3 April, 2023.
    [Contact:protected] => For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
    [Header:protected] => 
    [Keywords:protected] => Array
        (
            [0] => Episurf Medical
            [1] => EpiSurf
        )
    [QuickFacts:protected] => Array
        (
        )
    [Categories:protected] => Array
        (
        )
    [Videos:protected] => Array
        (
        )
    [Files:protected] => Array
        (
            [0] => CisionBlockPro\Cision\File Object
                (
                    [IsMain:protected] => 1
                    [MediaType:protected] => File
                    [Url:protected] => https://mb.cision.com/Main/14691/3745793/1961789.pdf
                    [FileName:protected] => wkr0006.pdf
                    [Title:protected] => New Canadian patent approval for Episurf Medical
                    [Description:protected] => New Canadian patent approval for Episurf Medical
                    [CreateDate:protected] => 2023-04-03T08:30:09.25Z
                    [Keywords:protected] => Array
                        (
                        )
                    [Extension:protected] => pdf
                )
        )
    [Quotes:protected] => Array
        (
        )
    [ExternalLinks:protected] => Array
        (
        )
    [EmbeddedItems:protected] => Array
        (
        )
    [Id:protected] => 4507613
    [EncryptedId:protected] => DA22338793F16A72
    [IsRegulatory:protected] => 1
    [PublishDate:protected] => 2023-04-03T08:30:00Z
    [LastChangeDate:protected] => 2023-04-03T08:30:09.233Z
    [Title:protected] => New Canadian patent approval for Episurf Medical
    [Intro:protected] => 
    [IptcCode:protected] => 04016003
    [InformationType:protected] => PRM
    [LanguageCode:protected] => en
    [CountryCode:protected] => se
    [CanonicalUrl:protected] => 
    [CisionWireUrl:protected] => https://news.cision.com/episurf/r/new-canadian-patent-approval-for-episurf-medical,c3745793
    [LanguageVersions:protected] => Array
        (
            [0] => CisionBlockPro\Cision\LanguageVersion Object
                (
                    [Code:protected] => sv
                    [ReleaseId:protected] => 4507611
                )
        )
    [Images:protected] => Array
        (
        )
    [Tickers:protected] => Array
        (
            [0] => stdClass Object
                (
                    [Symbol] => EPIS B
                    [ISIN] => SE0003491562
                    [PrimaryListing] => 1
                    [IsShare] => 1
                    [MarketPlaceSymbol] => STO
                    [MarketPlaceName] => Stockholmsbörsen
                    [MarketPlaceBloombergCode] => SS
                    [MarketPlaceMarketWireCode] => OMX
                    [MarketPlaceIsRegulated] => 1
                    [MarketPlaceCountryCode] => SE
                )
        )
)